{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:26:36Z","timestamp":1767709596260,"version":"3.48.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Turkish Society of Nephrology and partly from Novo Nordisk"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04653-8","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:54:13Z","timestamp":1764701653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diabetes and chronic kidney disease in Turkey (DIAKIT): a cross-sectional cohort study"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4055-7896","authenticated-orcid":false,"given":"Mustafa","family":"Arici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenan","family":"Ates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaattin","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali R.","family":"Odabas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Tokgoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siren","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halil Zeki","family":"Tonbul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif Ari","family":"Bakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Memnune Sena","family":"Ulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozkan","family":"Gungor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurhan","family":"Seyahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sim","family":"Kutlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Altun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"4653_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and National burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395:709\u201333.","journal-title":"Lancet"},{"key":"4653_CR2","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392:2052\u201390.","journal-title":"Lancet"},{"key":"4653_CR3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(19)32977-0","volume":"395","author":"P Cockwell","year":"2020","unstructured":"Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet. 2020;395:662\u20134.","journal-title":"Lancet"},{"key":"4653_CR4","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/ndt\/gfq656","volume":"26","author":"G S\u00fcleymanlar","year":"2011","unstructured":"S\u00fcleymanlar G, Uta\u015f C, Arinsoy T, Ate\u015f K, Altun B, Altiparmak MR, et al. A population-based survey of chronic renal disease in Turkey\u2013the CREDIT study. Nephrol Dial Transplant. 2011;26:1862\u201371.","journal-title":"Nephrol Dial Transpl"},{"key":"4653_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/kidneydial2030038","volume":"2","author":"EK Hoogeveen","year":"2022","unstructured":"Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney Dial. 2022;2:433\u201342.","journal-title":"Kidney Dial"},{"key":"4653_CR6","doi-asserted-by":"publisher","first-page":"248563","DOI":"10.1155\/2013\/248563","volume":"2013","author":"A Mima","year":"2013","unstructured":"Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its Inhibition as new therapeutic targets. J Diabetes Res. 2013;2013:248563.","journal-title":"J Diabetes Res"},{"key":"4653_CR7","unstructured":"International Diabetes Federation. International Diabetes Federation: Diabetes atlas. 2006. 3rd Ed. https:\/\/diabetesatlas.org\/upload\/resources\/previous\/files\/3\/Diabetes-Atlas-3rd-edition.pdf. Accessed 26 Nov 2024."},{"key":"4653_CR8","first-page":"19","volume":"9","author":"S K\u00f6z","year":"2016","unstructured":"K\u00f6z S, Kayata\u015f M. Diabetic nephropathy: epidemiology, pathogenesis, diagnosis [Diyabetik Nefropati; Epidemiyoloji, Patogenez, Tan\u0131]. Turkiye Klinikleri Nephrol - Special Top. 2016;9:19\u201327. (Article in Turkish).","journal-title":"Turkiye Klinikleri Nephrol - Special Top"},{"issue":"Suppl 1","key":"4653_CR9","first-page":"S3","volume":"17","author":"S van Dieren","year":"2010","unstructured":"van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(Suppl 1):S3\u20138.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"4653_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10654-013-9771-5","volume":"28","author":"I Satman","year":"2013","unstructured":"Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013;28:169\u201380.","journal-title":"Eur J Epidemiol"},{"key":"4653_CR11","unstructured":"IDF Diabetes Atlas. 10th Edition. 2021. Turkey Diabetes Report 2000\u20132045. https:\/\/diabetesatlas.org\/data\/en\/country\/203\/tr.html. Accessed 5 Mar 2024."},{"key":"4653_CR12","unstructured":"Ate\u015f K, Seyahi N, Ko\u00e7yi\u011fit I. May. Registry of the nephrology, dialysis and transplantation in Turkey - registry 2022. Ministry of Health and Turkish Society of Nephrology Joint Report. Ankara, November 2023. https:\/\/nefroloji.org.tr\/uploads\/pdf\/REGISTRY2022_web.pdf. Accessed 7 2024."},{"key":"4653_CR13","first-page":"190","volume":"16","author":"S Unal","year":"2018","unstructured":"Unal S, Ascioglu S, Demirkazik A, Ertenli \u0130, Eskioglu E, Guler K, et al. Baseline data of a prospective cohort study: cappadocia cohort study, Turkey. Turkish J Public Health. 2018;16:190\u2013203.","journal-title":"Turkish J Public Health"},{"issue":"4S","key":"4653_CR14","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"key":"4653_CR15","doi-asserted-by":"crossref","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. [Published correction appears in Ann Intern Med. 2011;155:408]. Ann Intern Med. 2009;150:604\u2009\u2013\u200912.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"4653_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12325-020-01568-8","volume":"38","author":"M Murton","year":"2021","unstructured":"Murton M, Goff-Leggett D, Bobrowska A, Garcia Sanchez JJ, James G, Wittbrodt E, et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. Adv Ther. 2021;38:180\u2013200.","journal-title":"Adv Ther"},{"key":"4653_CR17","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens. 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"key":"4653_CR18","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1681\/ASN.2015050542","volume":"27","author":"K Br\u00fcck","year":"2016","unstructured":"Br\u00fcck K, Stel VS, Gambaro G, Hallan S, V\u00f6lzke H, \u00c4rnl\u00f6v J, et al. CKD prevalence varies across the European general population. J Am Soc Nephrol. 2016;27:2135\u201347.","journal-title":"J Am Soc Nephrol"},{"key":"4653_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/08860220903219265","volume":"31","author":"I Sahin","year":"2009","unstructured":"Sahin I, Yildirim B, Cetin I, Etikan I, Ozturk B, Ozyurt H, et al. Prevalence of chronic kidney disease in the black sea Region, Turkey, and investigation of the related factors with chronic kidney disease. Ren Fail. 2009;31:920\u20137.","journal-title":"Ren Fail"},{"key":"4653_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000339025","volume":"36","author":"B Altun","year":"2012","unstructured":"Altun B, S\u00fcleymanlar G, Uta\u015f C, Ar\u0131nsoy T, Ate\u015f K, Ecder T, et al. Prevalence, awareness, treatment and control of hypertension in adults with chronic kidney disease in Turkey: results from the CREDIT study. Kidney Blood Press Res. 2012;36:36\u201346.","journal-title":"Kidney Blood Press Res"},{"key":"4653_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1471-2369-13-87","volume":"13","author":"G Coll-de-Tuero","year":"2012","unstructured":"Coll-de-Tuero G, Mata-Cases M, Rodriguez-Poncelas A, Pepi\u00f3 JM, Roura P, Benito B, et al. Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a mediterranean area. BMC Nephrol. 2012;13:87.","journal-title":"BMC Nephrol"},{"key":"4653_CR22","first-page":"552","volume":"30","author":"LM Lou Arnal","year":"2010","unstructured":"Lou Arnal LM, Campos Guti\u00e9rrez B, Cuberes Izquierdo M, Gracia Garc\u00eda O, Tur\u00f3n Alcaine JM, Bielsa Garc\u00eda S, et al. Prevalencia de Enfermedad renal cr\u00f3nica En Pacientes Con diabetes mellitus Tipo 2 atendidos En atenci\u00f3n primaria [Prevalence of chronic kidney disease in patients with type 2 diabetes mellitus treated in primary care]. Nefrologia. 2010;30:552\u20136. (Article in Spanish).","journal-title":"Nefrologia"},{"key":"4653_CR23","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2012.16817","volume":"308","author":"SI Hallan","year":"2012","unstructured":"Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349\u201360.","journal-title":"JAMA"},{"key":"4653_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12882-018-0821-9","volume":"19","author":"KC Norris","year":"2018","unstructured":"Norris KC, Smoyer KE, Rolland C, Van der Vaart J, Grubb EB. Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review. BMC Nephrol. 2018;19:36.","journal-title":"BMC Nephrol"},{"key":"4653_CR25","doi-asserted-by":"publisher","first-page":"e2326230","DOI":"10.1001\/jamanetworkopen.2023.26230","volume":"6","author":"CD Chu","year":"2023","unstructured":"Chu CD, Xia F, Du Y, Singh R, Tuot DS, Lamprea-Montealegre JA, et al. Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease. JAMA Netw Open. 2023;6:e2326230.","journal-title":"JAMA Netw Open"},{"key":"4653_CR26","doi-asserted-by":"publisher","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","volume":"2","author":"KR Tuttle","year":"2019","unstructured":"Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open. 2019;2:e1918169.","journal-title":"JAMA Netw Open"},{"key":"4653_CR27","doi-asserted-by":"publisher","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","volume":"20","author":"J Sundstr\u00f6m","year":"2022","unstructured":"Sundstr\u00f6m J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74 million patients from 11 countries: the careme CKD study. Lancet Reg Health Eur. 2022;20:100438.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"4653_CR28","doi-asserted-by":"publisher","first-page":"sfad137","DOI":"10.1093\/ckj\/sfad137","volume":"17","author":"SC Yeo","year":"2023","unstructured":"Yeo SC, Wang H, Ang YG, Lim CK, Ooi XY. Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review. Clin Kidney J. 2023;17(1):sfad137.","journal-title":"Clin Kidney J"},{"key":"4653_CR29","doi-asserted-by":"publisher","first-page":"11752","DOI":"10.3390\/ijerph182211752","volume":"18","author":"S Stolpe","year":"2021","unstructured":"Stolpe S, Kowall B, Scholz C, Stang A, Blume C. High unawareness of chronic kidney disease in Germany. Int J Environ Res Public Health. 2021;18:11752.","journal-title":"Int J Environ Res Public Health"},{"key":"4653_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jcjd.2022.01.008","volume":"46","author":"L Chu","year":"2022","unstructured":"Chu L, Bhogal SK, Lin P, Steele A, Fuller M, Ciaccia A, et al. AWAREness of diagnosis and treatment of chronic kidney disease in adults with type 2 diabetes (AWARE-CKD in T2D). Can J Diabetes. 2022;46:464\u201372.","journal-title":"Can J Diabetes"},{"key":"4653_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.pcd.2022.03.003","volume":"16","author":"P Ji","year":"2022","unstructured":"Ji P, Zhu J, Feng J, Li H, Yu Q, Qin H, et al. Serum uric acid levels and diabetic kidney disease in patients with type 2 diabetes mellitus: a dose-response meta-analysis. Prim Care Diabetes. 2022;16:457\u201365.","journal-title":"Prim Care Diabetes"},{"key":"4653_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pcd.2014.06.001","volume":"9","author":"K Mets\u00e4rinne","year":"2015","unstructured":"Mets\u00e4rinne K, Br\u00f6ijersen A, Kantola I, Niskanen L, Rissanen A, Appelroth T, et al. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care. Prim Care Diabetes. 2015;9:31\u20138.","journal-title":"Prim Care Diabetes"},{"key":"4653_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2369-14-46","volume":"14","author":"A Rodriguez-Poncelas","year":"2013","unstructured":"Rodriguez-Poncelas A, Garre-Olmo J, Franch-Nadal J, Diez-Espino J, Mundet-Tuduri X, Barrot-De la Puente J, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes in spain: PERCEDIME2 study. BMC Nephrol. 2013;14:46.","journal-title":"BMC Nephrol"},{"key":"4653_CR34","first-page":"41","volume":"1","author":"WM Sweileh","year":"2009","unstructured":"Sweileh WM, Sawalha AF, Zyoud SH, Al-Jabi SW 1, Shraim NY. Prevalence of reduced renal function among diabetic hypertensive patients. Int J Physiol Pathophysiol Pharmacol. 2009;1:41\u20137.","journal-title":"Int J Physiol Pathophysiol Pharmacol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04653-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04653-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04653-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:25:05Z","timestamp":1767709505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04653-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4653"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04653-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"All participants provided written informed consents for their participation in the study and agreed to provide their contact information and to be called at certain times. The study was approved by the Clinical Researches Ethics Committee of Ankara University Faculty of Medicine (dated: 06 June 2022, approval no: 12.540.22) and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was presented as a poster presentation at the 60th ERA Congress which was held on June 15\u201318, 2023 in Milan, Italy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior publication"}},{"value":"MA, KA, BT, SS, EAB, MSU, OG, SK, and BA have received funding support for the present manuscript from Turkish Society of Nephrology and partly from Novo Nordisk. MA has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Novo Nordisk, Recordati, Sandoz, and Sanofi and has participated on a Data Safety Monitoring Board or Advisory Board for Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk. KA has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Baxter, Amgen, AstraZeneca, and Astellas and has received support for attending meetings and\/or travel from Baxter, Amgen, Nobel. BT has received consulting fees from Chiesi, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Sanofi, Takeda, Amgen, Baxter, Novartis, AstraZeneca, Astellas, Nobel, Menarini, Fresenius Medical Care, Bayer, and Abdi \u0130brahim, and support for attending meetings and\/or travel from Bayer, Sanofi, Takeda, Baxter, Amgen, and Chinook, and participated on a Data Safety Monitoring Board or Advisory Board for Sanofi. SS has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Bayer, Boehringer Ingelheim, AstraZeneca, Amgen, GlaxoSmithKline and support for attending meetings and\/or travel from Bayer, Boehringer Ingelheim, AstraZeneca, Amgen. EAB has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Amgen, AstraZeneca, Boehringer Ingelheim, Bayer and support for attending meetings and\/or travel from Amgen, AstraZeneca, Bayer. MSU has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Bayer, Boehringer Ingelheim, AstraZeneca, Amgen, GlaxoSmithKline and support for attending meetings and\/or travel from Bayer, Boehringer Ingelheim, AstraZeneca, Amgen. BA has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Bayer, Boehringer Ingelheim, AstraZeneca, Amgen, GlaxoSmithKline and support for attending meetings and\/or travel from Bayer, Boehringer Ingelheim, AstraZeneca, Amgen. All the remaining authors- AY, ARO, HZT, NS -declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}